2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2023. In addition, publicly available 2023 sales data of biosimilar antibodies and proteins are included in the report. This report also includes sales data of new biologic modalities such as gene and cell therapy and RNA (antisense, siRNA).

Sales data were obtained from company publications. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 01, 2023. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases as constant exchange rates).

Sales data from more than 350 products form the basis of the report. In 2023, sales data from 50 new products have been added to the compilation: 28 innovator products, 15 biosimilars and seven novel biologic drug modalities.

In the analytical part of the report, sales data from 2012 to 2023 are summarized for the class of products and their growth rates reported:

• Cancer Antibodies
• Other Anti-Inflammatory mAbs
• Anti-TNF Antibodies
• Cardiometabolic Antibodies
• Ophthalmic Antibodies
• Insulin & Insulin Analogs
• Coagulation Factors
• Enzyme Replacement Therapy
• Established Therapeutic Proteins
• Anti-Infective Antibodies
• Migraine Antibodies
• Other Proteins

The percentage of antibody sales of total biologics sales was calculated.

Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins, and their sales data reported from 2012 to 2023.

Sales and growth rates of cancer antibodies were analyzed by subgroup:

• Anti-PD-1 & PD-L1 Antibodies (Abs)
• Other Immuno-Oncology (I-O) Abs
• Anti-Her2 Abs
• Anti-EGFR Abs
• Anti-VEGF/-R Abs
• Anti-CD20 Abs
• Other Cancer Abs

Sales and growth rates of anti-inflammatory antibodies different from anti-TNF antibodies analyzed by therapeutic area:

• Dermatology
• Rheumatoid & Autoimmune
• Neuro-Inflammation
• Pulmonary & Respiratory
• Gastrointestinal

Development of sales and growth rates of antibody-drug conjugates ADCs are presented for the years 2012 to 2023.

For the first time, sales and growth rates of bispecific antibodies and antibody combination therapies are shown for the year 2015 to 2023.

Company sales data for biosimilar antibodies and proteins are highlighted in a Table for the years 2020 to 2023 as published by the originator and commercializing companies.

Total published sales for novel biologic drug modalities, i.e. gene and cell therapy and RNA-based biologics (antisense, siRNA, PMOs), are presented.

Sales of innovator therapeutic antibodies and proteins were summarized per company and a ranking list was prepared for the TOP 30 companies according to biologics sales in 202.

A total of 69 biologic therapeutics reached blockbuster status with 2023 sales exceeding US$ 1 bln. For the first time, seven new antibody and protein products were included as Blockbuster Biologics for the year 2023, while nine Blockbuster Biologics in the year 2022 dropped out of the list, mainly SARS-CoV2 antibodies, but also established proteins.